BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 23215690)

  • 1. 2-Hydroxypropyl-β-cyclodextrin-modified SLN of paclitaxel for overcoming p-glycoprotein function in multidrug-resistant breast cancer cells.
    Baek JS; Cho CW
    J Pharm Pharmacol; 2013 Jan; 65(1):72-8. PubMed ID: 23215690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled release and reversal of multidrug resistance by co-encapsulation of paclitaxel and verapamil in solid lipid nanoparticles.
    Baek JS; Cho CW
    Int J Pharm; 2015 Jan; 478(2):617-24. PubMed ID: 25510604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solid lipid nanoparticles of paclitaxel strengthened by hydroxypropyl-β-cyclodextrin as an oral delivery system.
    Baek JS; So JW; Shin SC; Cho CW
    Int J Mol Med; 2012 Oct; 30(4):953-9. PubMed ID: 22859311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modification of paclitaxel-loaded solid lipid nanoparticles with 2-hydroxypropyl-β-cyclodextrin enhances absorption and reduces nephrotoxicity associated with intravenous injection.
    Baek JS; Kim JH; Park JS; Cho CW
    Int J Nanomedicine; 2015; 10():5397-405. PubMed ID: 26347363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanohybrid systems of non-ionic surfactant inserting liposomes loading paclitaxel for reversal of multidrug resistance.
    Ji X; Gao Y; Chen L; Zhang Z; Deng Y; Li Y
    Int J Pharm; 2012 Jan; 422(1-2):390-7. PubMed ID: 22001531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stability of paclitaxel-loaded solid lipid nanoparticles in the presence of 2-hydoxypropyl-β-cyclodextrin.
    Baek JS; Kim BS; Puri A; Kumar K; Cho CW
    Arch Pharm Res; 2016 Jun; 39(6):785-93. PubMed ID: 27146520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux.
    Chavanpatil MD; Patil Y; Panyam J
    Int J Pharm; 2006 Aug; 320(1-2):150-6. PubMed ID: 16713148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
    Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
    Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro cytotoxic activity of cationic paclitaxel nanoparticles on MDR-3T3 cells.
    Niu G; Castro CH; Nguyen N; Sullivan SM; Hughes JA
    J Drug Target; 2010 Jul; 18(6):468-76. PubMed ID: 20059301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cytological Study in vitro on Co-delivery of siRNA and Paclitaxel within Solid Lipid Nanoparticles to Overcome Multidrug Resistance in Tumors].
    Huang R; Yao X; Chen Y; Sun X; Lin Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2016 Feb; 33(1):108-14. PubMed ID: 27382749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug resistance reversal activity of anticancer drug loaded solid lipid nanoparticles in multi-drug resistant cancer cells.
    Miao J; Du YZ; Yuan H; Zhang XG; Hu FQ
    Colloids Surf B Biointerfaces; 2013 Oct; 110():74-80. PubMed ID: 23711779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lactoferrin-appended solid lipid nanoparticles of paclitaxel for effective management of bronchogenic carcinoma.
    Pandey V; Gajbhiye KR; Soni V
    Drug Deliv; 2015 Feb; 22(2):199-205. PubMed ID: 24467582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Difunctional Pluronic copolymer micelles for paclitaxel delivery: synergistic effect of folate-mediated targeting and Pluronic-mediated overcoming multidrug resistance in tumor cell lines.
    Wang Y; Yu L; Han L; Sha X; Fang X
    Int J Pharm; 2007 Jun; 337(1-2):63-73. PubMed ID: 17289311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-encapsulation of paclitaxel and baicalein in nanoemulsions to overcome multidrug resistance via oxidative stress augmentation and P-glycoprotein inhibition.
    Meng L; Xia X; Yang Y; Ye J; Dong W; Ma P; Jin Y; Liu Y
    Int J Pharm; 2016 Nov; 513(1-2):8-16. PubMed ID: 27596118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies.
    Wang S; Chen T; Chen R; Hu Y; Chen M; Wang Y
    Int J Pharm; 2012 Jul; 430(1-2):238-46. PubMed ID: 22465546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a potential carrier to overcome multidrug resistance in cervical and breast cancer.
    Wang F; Li L; Liu B; Chen Z; Li C
    Biomed Pharmacother; 2017 Feb; 86():595-604. PubMed ID: 28027535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Folate and CD44 receptors dual-targeting hydrophobized hyaluronic acid paclitaxel-loaded polymeric micelles for overcoming multidrug resistance and improving tumor distribution.
    Liu Y; Sun J; Lian H; Cao W; Wang Y; He Z
    J Pharm Sci; 2014 May; 103(5):1538-47. PubMed ID: 24619562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization and in vitro assessment of paclitaxel loaded lipid nanoparticles formulated using modified solvent injection technique.
    Pandita D; Ahuja A; Velpandian T; Lather V; Dutta T; Khar RK
    Pharmazie; 2009 May; 64(5):301-10. PubMed ID: 19530440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance.
    Wang F; Zhang D; Zhang Q; Chen Y; Zheng D; Hao L; Duan C; Jia L; Liu G; Liu Y
    Biomaterials; 2011 Dec; 32(35):9444-56. PubMed ID: 21903258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel-loaded N-octyl-O-sulfate chitosan micelles for superior cancer therapeutic efficacy and overcoming drug resistance.
    Jin X; Mo R; Ding Y; Zheng W; Zhang C
    Mol Pharm; 2014 Jan; 11(1):145-57. PubMed ID: 24261922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.